NGM Bio Announces Clinical Trial Collaboration with Merck Related to Ongoing Phase 1/2 Trial of NGM707, an ILT2/ILT4 Dual Antagonist Antibody, in Combination with Merck’s KEYTRUDA® (pembrolizumab)

NEXT STORY
180 Life Sciences Provides Follow-Up Information on Oxford University and the Company’s Successful Dupuytren’s Phase 2b Clinical Trial Results
PREV STORY
Cowen Research Identifies Themes That Will Define Industries and Drive Investment Performance In 2022
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

MyoKardia Doses First Patient in Phase 3 VALOR-HCM Trial of Mavacamten

author_avatar
NASDAQ Market News

Rafael Pharmaceuticals Announces Initiation of Pivotal Phase 3 Trial (AVENGER 500) of CPI-613 (devimistat) in Combination with Modified FOLFIRINOX as First Line Treatment for Patients with Metastatic Pancreatic Cancer

Interim analysis expected as early as Q2 2020Newark, NJ, Dec. 11, 2018 (GLOBE NEWSWIRE) ...

author_avatar
NASDAQ Market News

Sanofi : CHMP recommends approval of Dupixent® (dupilumab) for severe chronic rhinosinusitis with nasal polyposis  

author_avatar
NASDAQ Market News